Artoxan

Quick links to important sections

Artoxan

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artoxan

Quick Facts

Property Description
Active ingredient Tenoxicam
Form Tablet, Lyophilized powder for injection
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic compound

Artoxan: Defining the Nonsteroidal Anti-Inflammatory Drug (NSAID)

Artoxan is a prescription-only medicinal product containing the active ingredient Tenoxicam, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This compound is structurally recognized as belonging to the oxicams subclass, a group distinguished by a sustained action profile. The Tenoxicam compound is fully synthetic, possessing a unique thienothiazine structure that contributes to its prolonged systemic effect, which is significantly longer than that of many conventional NSAIDs. This extended presence in the body makes it clinically recognized for providing lasting management of symptoms associated with chronic inflammatory processes.

Composition and Available Pharmaceutical Forms

The product is fundamentally a single active ingredient product, relying exclusively on Tenoxicam for its therapeutic effects. It is primarily available as an oral tablet for convenient use and in a sterile lyophilized powder for injection form, which is intended for rapid administration when oral intake is unsuitable. The availability of both the oral and injectable forms is a crucial feature, facilitating prompt pain and inflammation management in acute clinical settings. Globally, Tenoxicam is also known by other trade names, such as Tilcotil, all sharing this core formulation. The dual availability ensures broad patient access to the anti-inflammatory effect depending on the patient's immediate clinical needs.

The General Purpose of Tenoxicam: Analgesic and Anti-inflammatory Action

The overarching purpose of this medicine is to provide relief from discomfort and symptoms arising from inflammatory processes and musculoskeletal pain. The therapeutic benefit is achieved through its mechanism of effect as a non-selective cyclooxygenase (COX) inhibitor. This inhibition limits the production of inflammatory prostaglandins, delivering a substantial anti-inflammatory effect that mitigates swelling and stiffness, alongside an effective analgesic effect that reduces the sensation of pain. The medicine is thus typically used in scenarios where persistent pain and swelling are present, offering a recognized therapeutic approach to improving comfort and function in affected individuals.

What side effects are possible with Artoxan?

Artoxan: Officially Documented Adverse Reactions and Safety Profile

The safety profile of Artoxan (Tenoxicam), as documented in official regulatory labeling, categorizes possible adverse reactions by the physiological system affected and their reported frequency of occurrence. The most frequently documented side effects are categorized as Common and often involve Gastrointestinal Disorders (such as dyspepsia, nausea, and abdominal pain) and Nervous System Disorders (including headache, dizziness, and fatigue). Reactions classified as Uncommon include stomatitis, rash, and sleep disturbances.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights the potential for serious adverse reactions, which are typically classified as rare. These include potentially life-threatening risks associated with the drug’s Nonsteroidal Anti-Inflammatory Drug (NSAID) class, such as gastrointestinal bleeding, ulceration, and perforation, which can occur at any time during treatment. Additionally, official documents specify a risk of serious cardiovascular thrombotic events (like myocardial infarction and stroke) and severe skin reactions, such as Stevens-Johnson Syndrome (SJS).

Population-Specific Safety: The regulatory label notes that older adults are at a higher risk for serious gastrointestinal events. The risk of cardiovascular thrombotic events may also be greater with higher doses or long-term use. The medicine is strictly contraindicated in individuals with active peptic ulceration, a history of gastrointestinal bleeding, severe heart failure, severe renal or hepatic impairment, and during the third trimester of pregnancy.

This structure ensures that the safety information communicates both the common effects and the rare, serious safety constraints explicitly defined by governing health authorities.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information regarding overdose for Artoxan (Tenoxicam) is based on the documented toxicity profile of its drug class, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).


Overdose Scope

Element Official Regulatory Statement (Tenoxicam/NSAID Class)
Documented overdose presentations Overdose may involve gastrointestinal effects, including abdominal pain, nausea, and vomiting, as well as CNS symptoms such as drowsiness, dizziness, confusion, and tinnitus.
Physiological systems affected Potential for severe effects on the Gastrointestinal system (bleeding, perforation), Renal system (acute failure), Central Nervous System (convulsions, coma), and Cardiovascular system (hypotension).
Population-specific overdose notes Elderly patients are documented as being at increased risk for serious or fatal gastrointestinal bleeding, ulceration, and perforation resulting from NSAID toxicity.
Emergency-response statements Contact a poison control centre for procedural guidance in the management of a suspected drug overdose.
When immediate medical help is required Seek medical attention immediately if symptoms of serious systemic events occur, such as chest pain, shortness of breath, sudden weakness, or slurred speech.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement (Tenoxicam/NSAID Class)
Severity classification Overdose is associated with the risk of severe and life-threatening outcomes, including GI bleeding, acute renal failure, and neurological sequelae.

Resulting Overdose Structure

Official overdose statements:

  • Supportive and symptomatic therapy is indicated as the primary management approach.
  • No specific antidote is known for the reversal of effects.
  • Hospital monitoring and observation are required to manage potential delayed systemic toxicity.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile for Artoxan by the severe systemic risks inherent to its NSAID classification. The management strategy is mandated as entirely procedural and supportive due to the lack of a known antidote. Immediate contact with emergency services is required for all suspected cases to mitigate life-threatening complications.

Therapeutic Uses of Artoxan

What Artoxan Treats: Main Uses and Benefits

Artoxan is commonly used to help with the relief of symptoms related to inflammatory or irritative states across several key musculoskeletal domains.

Symptomatic Management of Chronic Arthritis and Joint Pain

This therapeutic domain covers the long-term, supportive relief from pain, stiffness, and inflammation associated with chronic joint conditions. The medication is commonly applied in conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It provides consistent symptomatic relief that helps patients cope more steadily with difficult episodes and may support improved day-to-day comfort and stability during symptomatic periods.

Relief from Acute Musculoskeletal and Soft Tissue Inflammation

Artoxan is relevant for clinical settings marked by the sudden appearance or escalation of symptoms in soft tissue structures, including tendinitis, bursitis, and the discomfort of strains and sprains. The use is centered on addressing symptoms that cluster into patterns requiring supportive management, such as localized swelling and sharp pain, and is relevant when short-term symptomatic assistance is needed during acute phases.

Treating Episodic Painful Flare-Ups and Cyclical Discomfort

This medicine is used across domains where short-term symptomatic assistance is appropriate for intense, episodic manifestations. This includes managing the pronounced symptoms of an acute gout attack and relieving cyclical, severe menstrual cramps (primary dysmenorrhea). It is applied when symptoms create noticeable interference with daily stability, contributing to easing the overall symptom load of these disruptive manifestations.

Quick Fact: Support for Symptoms Related to Inflammation

Symptom Axis Therapeutic Benefit
Musculoskeletal Pain Helps ease discomfort at rest and during movement
Inflammation/Swelling Supports the management of localized swelling
Stiffness/Rigidity May assist with maintaining functional stability

Regulatory References

  1. Product Monograph of Tenoxicam

Eligibility and Restrictions for Use

The eligibility profile for Artoxan (Tenoxicam) defines specific populations permitted to use the medicine and those for whom use is strictly prohibited or restricted. Artoxan is generally allowed for use in adults (typically 16 years and older) for the symptomatic management of its indicated musculoskeletal conditions.

Eligibility Status

Status Key Constraints
Contraindicated Severe Organ Failure (Heart, Hepatic, or Kidney). GI Risk (Active/recurrent ulcers, bleeding history, or haemorrhagic diathesis). Hypersensitivity (Known allergy to tenoxicam or other NSAIDs). Third Trimester of Pregnancy.
Not Recommended Pediatric patients (under 16 years of age) as dose and indications are not established. Lactation and the first/second trimesters of pregnancy.

Use is subject to special caution and monitoring in older adults due to increased risk of adverse reactions. Furthermore, patients with mild to moderate renal or hepatic impairment or uncontrolled cardiovascular conditions (e.g., hypertension) should only use Artoxan after careful regulatory consideration and with close surveillance of their pre-existing condition. This structure establishes clear, mandatory constraints on who can and cannot use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Artoxan (Tenoxicam) is defined by two primary domains: pharmacodynamic reinforcement and pharmacokinetic alteration of co-administered substances, as documented in regulatory information. Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and analgesic doses of Aspirin is generally restricted or contraindicated due to the documented increase in gastrointestinal adverse effects.

Several medicinal product categories are associated with clinically significant interactions:

Interacting Substance Category Official Interaction Outcome
Anticoagulants/Anti-platelet Agents/SSRIs Documented increased risk of bleeding or gastrointestinal ulceration.
Diuretics/Antihypertensives May diminish the antihypertensive effect and increase the risk of nephrotoxicity or renal failure.
Lithium/Methotrexate May significantly increase the plasma levels and reduce the clearance of the co-administered drug.

A timing constraint exists for Mifepristone, as Tenoxicam should not be used for 8–12 days after administration to avoid documented interference. For food intake, official regulatory sources state it reduces the rate of absorption of Tenoxicam but not the total extent of absorption. Furthermore, regulatory documents specify that Elderly Patients have a heightened susceptibility to serious adverse effects from interactions, necessitating specific consideration during concomitant therapy.

Mechanism of Action

The action of Artoxan (Tenoxicam) is defined by its multi-target mechanism that intervenes directly in the biological cascades driving inflammatory and nociceptive signaling.

Enzyme Inhibition: Modulating Prostaglandin Synthesis

The primary mechanism involves the non-selective and reversible inhibition of Cyclooxygenase (COX) enzymes, specifically mathbfCOX-1 and mathbfCOX-2. This action blocks the crucial step in the arachidonic acid cascade where pro-inflammatory mediators, such as prostaglandins, are synthesized. The resulting physiological effect is a diminished sensitization of nociceptors and a modulation of localized vascular changes.

Cellular Stabilization and Tissue Modulation

In addition to enzyme blockade, the drug engages secondary mechanisms. This includes stabilizing lysosomal membranes within inflammatory cells, which restricts the release of hydrolytic enzymes into the surrounding tissue. Furthermore, the drug acts centrally on the hypothalamus to reduce prostaglandin synthesis, thereby modulating the central thermoregulatory set-point and influencing the systemic thermal response.

Mechanism Limitation: Non-Selective COX-1 Interference

The mechanism involves the simultaneous, non-selective inhibition of constitutive COX-1. While the primary effects target the inducible mathbfCOX-2, blocking mathbfCOX-1 also suppresses the synthesis of prostaglandins that maintain physiological processes, such as gastric mucosal function and renal blood flow regulation.

Dosage and Administration Information

How to Use Artoxan (Tenoxicam) — Administration Guidelines

This section outlines the standardized usage instructions for Artoxan (Tenoxicam), describing the typical administration and dosing patterns for the medication.

Dosage and Administration

The medicine is available in two main formats: film-coated tablets for oral use and lyophilized powder for injection (for reconstitution and parenteral use).

Administration Route Standard Dosing Rule Condition-Specific Dosing
Oral (Tablets) 20 mg as a single daily dose. For chronic disorders, a 10 mg maintenance dose may be attempted.
Parenteral (IV/IM) 20 mg once daily. Used for initiating treatment (1–2 days) before switching to the oral form.

Frequency, Timing, and Preparation

  • Frequency: The medicine must be taken once daily.
  • Timing: Tablets should be swallowed whole, preferably with or immediately after a meal.
  • Preparation (Injection): The lyophilized powder must be dissolved using the accompanying solvent and the resulting solution should be used immediately. The reconstituted solution is for IV or IM bolus injection; use in infusions is not recommended.
  • Acute Gout: Treatment starts with an initial dose of 40 mg once daily for two days, followed by 20 mg daily for an additional five days.
  • Duration: For acute conditions, treatment should generally not exceed 7 days.

Population-Specific Instructions

Elderly Patients and those with renal or hepatic impairment should receive the lowest effective dose for the shortest duration necessary, with careful monitoring as directed by the prescribing authority.

Recent Clinical Evidence

Artoxan: Recent Clinical Evidence


Overview of Studies for Chronic Joint Inflammation

Artoxan, containing Tenoxicam, was evaluated in conditions characterized by functional limitations, such as rheumatoid arthritis (RA) and osteoarthritis (OA). Research primarily utilized short-term randomized controlled trials (RCTs) to examine how symptoms change over time in adult populations. These studies monitored patient-reported outcomes describing perceived discomfort, including pain intensity scores and functional capacity assessments. Findings describe patterns observed in the studies where participants experienced changes measured during the study period across these symptom categories. In many trials, the data show patterns related to measured symptom change that was observed to be similar to those reported for comparators studied in the same context. Research so far indicates that these studies primarily focus on short-term symptom changes over periods often lasting between four and twelve weeks. The long-term effects on the underlying conditions are not fully established by these initial trials, which prioritize symptomatic outcomes. The results apply only to the populations studied.


Studies for Acute Musculoskeletal and Episodic Pain

Research has also evaluated Tenoxicam in settings involving acute or disruptive episodes, such as localized soft tissue inflammation (like tendinitis) and acute gout. These short-term studies focused on outcomes related to physical discomfort, including localized swelling and pain. The findings describe patterns observed in the studies related to changes in localized symptoms during the acute phase. It is noted that for certain acute pain models, the comparative evidence is lacking with respect to newer agents, and the evidence quality varies across studies depending on the specific indication.


Long-Term Evidence and Uncertainty

Limited evidence includes open-label clinical extensions that have monitored patients for extended periods, providing context but not individual predictions on the sustainability of observed symptom patterns. Long-term effects are not fully established by the primary RCT evidence. Furthermore, official research summaries indicate that data for certain groups remain insufficient, including children, adolescents, and many specific subgroups defined by complex comorbidities. Overall, while the evidence contributes to the broader landscape of pain management, certainty remains low in areas outside of core short-term outcomes related to physical discomfort.

Key Studies & References Tenoxicam Product Monograph (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Artoxan (FAQ)


Q: How quickly does Artoxan start to have an effect?

A: Studies and official information indicate that for conditions like chronic joint inflammation, effects can be noted early in treatment. However, because the medicine takes a while to build up in the body—reaching steady levels around 10 to 15 days—the full effect may be progressive over the first few weeks.


Q: Can people with kidney problems take Artoxan?

A: Official regulatory documentation states that this medicine is described in official documents as generally contraindicated in individuals with severe kidney impairment. For those with mild or moderate kidney issues, treatment is initiated at the lowest possible dose, and careful monitoring is often indicated, as use may carry a risk of kidney injury.


Q: Is Artoxan suitable for older adults?

A: Regulatory information indicates that the elderly population is documented as having an increased susceptibility to serious adverse effects, particularly related to the stomach and intestines. For this reason, official guidelines recommend using the lowest effective dose for the shortest possible time, alongside careful monitoring.


Q: Can Artoxan be used during pregnancy, according to official information?

A: Official documentation advises against the use of this medicine during the first two trimesters of pregnancy. Furthermore, it is described as contraindicated (must not be used) starting from the third trimester, approximately 28 weeks, due to documented potential risks to the developing fetus.


Q: Is there official guidance on Artoxan use during breastfeeding?

A: Official documentation generally advises against using this medicine while breastfeeding. Although the amount that passes into breast milk is often low, the potential risk to the breastfed infant cannot be ruled out according to official regulatory assessments.


Q: Does Artoxan have a 'black box warning' in the US?

A: While the specific drug may or may not be marketed in the US, similar medicines in the same Nonsteroidal Anti-Inflammatory Drug (NSAID) class carry a US FDA Boxed Warning. This general warning highlights an increased risk of serious cardiovascular events, like heart attack or stroke, and serious gastrointestinal events, such as bleeding and ulceration.


Q: What is the current research consensus on Artoxan's effectiveness?

A: Research summarized in official documents indicates that the medicine has been evaluated in short-term studies for relief of symptoms in chronic joint conditions. The findings describe changes in measured symptoms observed to be similar to those reported for certain other comparator drugs studied in the same context. However, the initial trials primarily focus on short-term outcomes, and long-term effectiveness is not fully established by this evidence.


Q: What happens if a dose of Artoxan is missed?

A: If a dose is missed, general guidance for once-daily medication suggests taking it as soon as it is remembered on the same day. However, if it is close to the next scheduled dose, the regulatory approach is generally to skip the dose and continue the regular schedule, avoiding taking two doses at once.


Q: What are the signs of a serious, but rare, side effect from Artoxan?

A: Official documentation lists rare signs that may indicate a serious reaction. These can include symptoms suggestive of internal bleeding (e.g., black or tarry stools), severe allergic reactions (e.g., swelling, severe rash), or liver issues (e.g., jaundice). Individuals experiencing these should seek immediate medical assistance, as described in patient safety information.


Q: Do I need to change my diet while taking Artoxan?

A: Regulatory information does not mandate broad dietary changes while using this medicine. The only instruction related to meals is that the tablet should be taken with or immediately after food to help reduce stomach irritation.


Q: Is Artoxan known to cause weight gain or loss?

A: Official side effect documentation lists oedema, which is fluid retention and swelling, as a potential documented side effect of medicines in the NSAID class. This effect can sometimes be related to changes in body weight.


Q: Is it safe to drive or operate machinery while taking Artoxan?

A: Official documentation advises caution because the medicine may cause side effects such as dizziness, drowsiness, or visual disturbances in some people. If these effects occur, official documentation indicates that activities requiring mental alertness, such as driving or operating machinery, should be avoided until the effects resolve.


Q: Is Artoxan known to cause changes in mood or sleep?

A: Official lists of documented side effects include rare psychiatric and nervous system effects. these can include nervousness, confusion, depression, hallucinations, and sleep disturbances like insomnia or nightmares.


Q: Can Artoxan interact with common vitamins?

A: Regulatory guidance advises consulting a healthcare professional before combining this medicine with any other medications. This includes non-prescription products, vitamins, or natural health supplements, as potential interactions must be considered by a healthcare provider.


Q: What is the meaning of the specific safety class Artoxan belongs to?

A: Artoxan belongs to the class of medicines known as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This class is described as working by reducing certain substances in the body that are responsible for causing inflammation, pain, and fever.


Q: Does Artoxan require any special monitoring or lab tests?

A: Official guidelines advise regular monitoring of certain body functions, particularly for patients receiving long-term treatment or those who have existing kidney or liver issues. This monitoring often involves checking blood count, kidney function, and liver function.


Q: Why are people with a history of heart issues advised caution with Artoxan?

A: Official regulatory warnings state that medicines in the NSAID class may be associated with a small increased risk of serious cardiovascular events, such as heart attack or stroke. Caution is specifically advised for patients who have established heart disease, or related risk factors, or uncontrolled high blood pressure.


Q: How does Artoxan affect the liver?

A: Official safety information notes that the drug is described as relatively contraindicated in patients with severe liver dysfunction. Rare cases of liver enzyme elevation, severe hepatitis, and jaundice have been documented, and monitoring of liver function is recommended for long-term use.


Q: Does Artoxan interact with anesthesia used for surgery?

A: Official patient information often contains a caution that the medicine should be stopped before a planned operation. This caution is related to the drug's effect on blood clotting, and official guidance suggests the medicine should be stopped before a planned operation.


Q: What is the typical time frame for re-evaluating treatment with Artoxan?

A: For acute pain conditions, regulatory guidance often advises limiting the treatment duration so that it does not exceed 7 days. For chronic use, the treatment is typically assessed by the prescribing authority after a short period, as many clinical trials examine effectiveness over four to twelve weeks.


Q: How long can I expect the effect of Artoxan to last?

A: The medicine is designed for once-daily use because it has a long elimination half-life, which is approximately 72 hours. This long duration helps ensure steady levels of the drug are maintained in the body throughout the day.


Q: How is Artoxan eliminated from the body?

A: After the medicine is processed by the body, the drug and its inactive forms are eliminated in roughly equal amounts. This elimination occurs through both the urine and the bile.


Q: Is it true that Artoxan can cause fatigue?

A: Official side effect documentation lists fatigue, sleepiness, and general tiredness as reported undesirable effects of the drug. Such effects are described in the safety information, and questions about side effects are best addressed by a healthcare provider.


Q: Are the side effects of Artoxan dose-dependent?

A: Official regulatory warnings explicitly state that the risk of serious side effects, especially gastrointestinal issues like bleeding or ulceration, increases with higher doses and longer duration of treatment.

How should Artoxan be stored and disposed of?

How to Store and Dispose of Artoxan?

Storage of Artoxan (Tenoxicam) must strictly follow the conditions detailed in official regulatory labeling to ensure product stability and effectiveness.


Storage Requirements

Condition Requirement
Temperature Store at or below 30 C (86 F)
Protection Keep protected from light and stored in a dry place (moisture)
Container Keep in a tightly closed container
Safety Store out of the reach of children and pets

Disposal Instructions

Official disposal guidelines mandate using a drug take-back program as the preferred method for unused or expired medication. If a take-back option is unavailable, Artoxan can be mixed with an unappealing substance, sealed in a bag, and placed in household trash. Do not flush this medication down a toilet or pour it down a drain. All personal information must be scratched out from the label before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artoxan found in:

A-Z Index: